Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

IASO206 bei Patienten mit rezidiviertem/refraktärem multiplem Myelom

Eine explorative Studie zur Sicherheit und Wirksamkeit von IASO206 bei Patienten mit rezidiviertem/refraktärem multiplem Myelom

This study is an open-label, single-arm early exploratory clinical study, aiming to evaluate the safety, tolerability and preliminary efficacy of IASO206 Injection(In Vivo CAR-T) in Patients with Relapsed/Refractory Multiple Myeloma

Studienübersicht

Status

Rekrutierung

Intervention / Behandlung

Studientyp

Interventionell

Einschreibung (Geschätzt)

18

Phase

  • Frühphase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

      • Tianjin, China
        • Rekrutierung
        • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences
        • Kontakt:
        • Hauptermittler:
          • gang An

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre bis 75 Jahre (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • 18 to 75 years old, male or female;

  • Diagnosed with relapsed/refractory multiple myeloma (RRMM) according to IMWG criteria, and have received at least 2 lines of treatment including one proteasome inhibitor and one immunomodulator; with documented disease progression (based on examination data) during or within 12 months after the latest anti-myeloma treatment (subjects whose last-line treatment was CAR-T therapy are not required to have progression within 12 months);

  • Presence of measurable lesions during screening according to any of the following criteria:

    • Serum monoclonal protein (M-protein) level: ≥5 g/L f;
    • Urine M protein level ≥200 mg/24 hours;
    • Light chain multiple myeloma without measurable lesions in serum or urine: the affected serum free light chain ≥100 mg/L with abnormal serum κ/λ free light chain ratio;
  • BCMA expression on MM cells determined by flow cytometry or pathology immunohistochemistry;

  • ECOG score ≤ 2;

  • Expected survival time ≥12 weeks;

  • Subjects must have adequate organ function:

  • Hematology: Absolute neutrophil count (ANC) ≥ 1×10^9/L (supportive treatment within 7 days before laboratory test is not allowed); Absolute lymphocyte count (ALC) )≥0.3×10^9/L; platelets≥50×10^9/L (blood transfusion support within 7 days before laboratory test is not allowed); hemoglobin ≥60 g/L (without red blood cell [RBC] transfusion within 7 days before laboratory test);

    • Liver function: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)≤1.5×upper limit of normal (ULN); serum total bilirubin≤1.5×ULN;
    • Renal function: creatinine clearance calculated according to Cockcroft-Gault formula≥ 40 ml/min.
    • Coagulation function: fibrinogen ≥1.0 g/L; activated partial thromboplastin time≤1.5×ULN, prothrombin time (PT)≤1.5×ULN;
    • Blood oxygen saturation>91%;
    • Left ventricular ejection fraction (LVEF) ≥50%;
  • Subjects and their spouses agree to use effective contraceptive methods with tools or drugs from the time the subject signs the informed consent form until one year after administration;

  • Subjects must sign a written informed consent form approved by the ethics committee before initiating the screening process.

Exclusion Criteria:

  • Patients with suspected or confirmed central nervous system involvement by plasma cell neoplasms;

  • Multiple myeloma patients with plasma cell leukemia;

  • Patients with amyloidosis;

  • Patients who have received autologous hematopoietic stem cell transplantation (Auto-HSCT) within 12 weeks before enrollment, or have a history of allogeneic hematopoietic stem cell transplantation (Allo-HSCT);

  • Patients who have received previous BCMA-targeted therapy;

  • Patients who have received plasma cell-targeted cellular therapy within 3 months before the screening period, or in whom received cellular therapy products can still be detected in peripheral blood;

  • Patients who have received other anti-tumor treatments requires an appropriate washout period:

    • Received Bendamustine, fludalabine or high-dose cyclophosphoyl within 9 months before enrollment,or;
    • Received Monoclonal antibody treatment for multiple myeloma within 21 days before enrollment, or;
    • Received cytotoxic chemotherapy or proteasome inhibitor treatment within 14 days before enrollment, or;
    • Received immunomodulatory treatment within 7 days before enrollment, or;
    • Received other anti-tumor treatments (including but not limited to experimental drugs) listed above within 14 days before enrollment or at least 5 half-lives (whichever is longer);
  • Patients requiring long-term use of therapeutic doses of corticosteroids during the study period (defined as prednisone or equivalent >20 mg/day), except for physiological replacement, topical, and inhaled use;

  • Severe heart diseases:including but not limited to unstable angina, myocardial infarction (within 6 months before screening), congestive heart failure (New York Heart Association [NYHA] classification ≥ grade III), severe arrhythmia,hypertension that cannot be controlled by medication;

  • Unstable systemic diseases judged by the investigator: including but not limited to severe liver, kidney or metabolic diseases;

  • Patient who needs chronic use of immunosuppressive agents;

  • Patients with malignant tumors other than multiple myeloma within 5 years before screening, excluding fully treated cervical carcinoma in situ, basal cell or squamous cell skin cancer, local prostate cancer after radical resection, and those after radical resection Ductal carcinoma in situ of breast and papillary thyroid carcinoma;

  • Patients with a history of solid organ transplantation;

  • Major surgery history within 2 weeks before entering the study, or scheduled surgery during the study period or within 2 weeks after the study treatment;

  • Serious uncontrolled infections during screening: Bacterial, viral, fungal, etc. infections;

  • Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) and detectable hepatitis B virus (HBV) DNA in peripheral blood; hepatitis C virus (HCV) antibody positive and peripheral blood hepatitis C virus ( HCV) RNA positive; human immunodeficiency virus (HIV) antibody positive; cytomegalovirus (CMV) DNA test positive; syphilis test positive;

  • Patients who have received inactivated vaccines within 4 weeks before enrollment;

  • Women who are pregnant or breastfeeding;

  • Patients with mental illness, consciousness disorder, or central nervous system diseases, including but not limited to epilepsy or a history of Parkinson's disease;

  • Known severe allergic reaction to IASO206 or its formulation components (such as tocilizumab);

  • Patients with unresolved non-hematological toxic reactions from previous treatments, which have not returned to baseline or ≤Grade 1 (except for alopecia and Grade 2 peripheral neuropathy);

  • Other situations considered unsuitable by the investigator.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: N / A
  • Interventionsmodell: Einzelgruppenzuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: IASO206

IASO206 will be administered in one infusion.

The third-generation self-inactivating lentiviral vector that carries a BCMA-targeted CAR.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
The incidence and severity of adverse events(AEs)
Zeitfenster: up to 2 years after IASO206 infusion

Cytokine release syndrome (CRS) and ICANS would be graded according to the ASTCT consensus.

All other AEs would be assessed according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0).

up to 2 years after IASO206 infusion

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Overall response rate (ORR)
Zeitfenster: up to 2 years after IASO206 infusion

The proportions of subjects achieving stringent Complete Response (sCR), Complete Response (CR), Very Good Partial Response (VGPR), and Partial Response (PR) after IASO206 infusion.

up to 2 years after IASO206 infusion
Time to response (TTR)
Zeitfenster: up to 2 years after IASO206 infusion

The time from the start of the drug infusion in subjects to the first occurrence of sCR, CR, VGPR, or PR.

up to 2 years after IASO206 infusion
MRD negativity rate
Zeitfenster: up to 2 years after IASO206 infusion

The proportion of subjects who achieve MRD-negativity after IASO206 infusion.

up to 2 years after IASO206 infusion
Duration of response (DOR)
Zeitfenster: up to 2 years after IASO206 infusion

The time from the first assessment of sCR or CR or VGPR or PR to the first assessment of disease progression or death from any cause.

up to 2 years after IASO206 infusion
Progression-free survival (PFS)
Zeitfenster: up to 2 years after IASO206 infusion

The time from the date IASO206 infusion to the date of first disease progression or death from any cause (whichever occurs first)

up to 2 years after IASO206 infusion
Overall survival (OS)
Zeitfenster: up to 2 years after IASO206 infusion

The time from the date of IASO206 infusion to the date of death from any reason.

up to 2 years after IASO206 infusion
Pharmacodynamics(PD)
Zeitfenster: up to 2 years after IASO206 infusion

The levels of cytokines (IL-6, serum ferritin, CRP) in peripheral blood at each time point,and lymphocyte subsets after IASO206 infusion.

up to 2 years after IASO206 infusion
Pharmacokinetic Analysis(PK)
Zeitfenster: up to 24 month after IASO206 infusion

Maximum concentration (Cmax) of IASO206 particle and CAR-T cells.

up to 24 month after IASO206 infusion
Pharmacokinetic Analysis(PK)
Zeitfenster: up to 24 month after IASO206 infusion

Time of maximum concentration (Tmax) of IASO206 particle and CAR-T cells.

up to 24 month after IASO206 infusion
Pharmacokinetic Analysis(PK)
Zeitfenster: up to 24 month after IASO206 infusion

Area under the concentration versus time curve: IASO206 particle AUC0-12d; CAR-T cell AUC0-28d,AUC0-90d,AUC0-180d,AUC0-last

up to 24 month after IASO206 infusion

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

8. Januar 2026

Primärer Abschluss (Geschätzt)

15. Dezember 2026

Studienabschluss (Geschätzt)

15. Oktober 2028

Studienanmeldedaten

Zuerst eingereicht

9. Dezember 2025

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

22. Dezember 2025

Zuerst gepostet (Tatsächlich)

7. Januar 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

9. November 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

6. November 2026

Zuletzt verifiziert

1. November 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren